MBM-55
CAS No. 2083622-09-5
MBM-55( —— )
Catalog No. M26289 CAS No. 2083622-09-5
MBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 326 | In Stock |
|
| 5MG | 297 | In Stock |
|
| 10MG | 432 | In Stock |
|
| 25MG | 662 | In Stock |
|
| 50MG | 849 | In Stock |
|
| 100MG | 1144 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 2316 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMBM-55
-
NoteResearch use only, not for human use.
-
Brief DescriptionMBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.
-
DescriptionMBM-55 is an effective inhibitor of NIMA related kinase 2 (NEK2) with an IC50 of 1 nM. MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis.(In Vitro):MBM-55 (0.5-1 μM; 24 hours) induces G2/M phase arrest and accumulation of cells with >4N content in HCT-116 cells. MBM-55 (0.5-1 μM; 24 hours) causes cell apoptosis in a concentration-dependent manner in HCT-116 cells.MBM-55 inhibits MGC-803, HCT-116, Bel-7402 cells proliferation with IC50s of 0.53, 0.84, 7.13 μM, respectively.(In Vivo):In female BALB/c nu/nu mice bearing HCT-116 xenografts, MBM-55 (20 mg/kg; i.p.) exhibits good antitumor activity and a well-tolerated dose schedule. MBM-55 (1.0 mg/kg; i.v.) shows the CL, Vss, T1/2, AUC0-t, and AUC0-∞ values of 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
-
In VitroCell Cycle Analysis Cell Line:HCT-116 cells Concentration:0.5, 1 μM Incubation Time:24 hours Result:Induced G2/M phase arrest and accumulation of cells with >4N content.Apoptosis Analysis Cell Line:HCT-116 cells Concentration:0.5, 1 μM Incubation Time:24 hours Result:Caused cell apoptosis in a concentration-dependent manner.
-
In VivoAnimal Model:Female BALB/c nu/nu mice (5-6 weeks, bearing HCT-116 xenografts) Dosage:20 mg/kg Administration:Intraperitoneal injection; twice a day for 21 days Result:Significantly suppressed tumor growth.Animal Model:Male Sprague Dawley (SD) rats Dosage:1.0 mg/kg Administration:IV injection (Pharmacokinetic Analysis)Result:The CL, Vss, T1/2, AUC0-t, and AUC0-∞ values were 33.3 mL/min/kg, 2.53 L/kg, 1.72 hours, 495 ng/h/mL and 507 ng/h/mL, respectively.
-
Synonyms——
-
PathwayPI3K/Akt/mTOR signaling
-
TargetGSK-3
-
RecptorAChE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2083622-09-5
-
Formula Weight498.562
-
Molecular FormulaC28H27FN6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (250.73 mM)
-
SMILESCN(C)CCn1cc(cn1)-c1ccn2c(cnc2c1)-c1ccc(C(N)=O)c(OCc2cccc(F)c2)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Wang Y, Dong Y, et al. Acephate interferes with androgen synthesis in rat immature Leydig cells. Chemosphere. 2020 Apr;245:125597.
molnova catalog
related products
-
GS87
GS87 is a highly specific inhibitor of GSK3 (glycogen synthase kinase 3) that induces extensive differentiation of AML cells.GS87 potently inhibits growth of AML cells in mice with little effect on normal bone marrow cells. GS87 causes terminal differentiation of AML cells.
-
GSK-3β inhibitor 11
GSK-3β inhibitor 11 (compound 21) is a potent glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 10.02 μM, demonstrating potential utility in neurodegenerative disease research .
-
PF-04802367
A potent, highly selective GSK-3 inhibitor with IC50 of 2.1 nM for human GSK-3β in enzyme assays.
Cart
sales@molnova.com